3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol, monohydrochloride (CAS NO:175591-09-0)

This compound is a key intermediate in the synthesis of Venlafaxine, an antidepressant in the serotonin-norepinephrine reuptake inhibitor (SNRI) class. The monohydrochloride salt provides enhanced stability and ease of handling for large-scale pharmaceutical synthesis.

Industries

Pharmaceutical

Sub-category

CNS Agents, Phenolic Compounds

Fast Response

Get a Quote

Details add in quote!

Minimum Order Quantity

Included in Quote

Lead Time

Included in Quote

Regional Availability

Included in Quote

Incoterms

Included in Quote

Chemical Properties & Specifications

Applications of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol, monohydrochloride

Pharmaceutical Synthesis

Intermediate for the synthesis of Venlafaxine Hydrochloride.

API Manufacturing

Used in large-scale production of CNS therapeutic agents.

End use- Drug Formulations

Integral part of the Venlafaxine API production line.

End use- CNS Therapeutic Drugs

Supplies intermediates to pharmaceutical companies for antidepressant medications.

Have Questions About 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol, monohydrochloride?
We've Got Answers.

What is the industrial significance of this Venlafaxine Intermediate? Essential for high-volume production of Venlafaxine Hydrochloride, a major CNS therapeutic.

Offers a chiral-specific precursor for developing antidepressants in the SNRI class. An important step in manufacturing Venlafaxine, used in treating major depressive disorder (MDD) and anxiety.

What are the handling considerations for this intermediate?

Requires GMP-compliant manufacturing and documentation for quality assurance. Ensure chiral purity and stability for downstream API synthesis. This is a raw material used in medicine manufacturing, not for direct consumer use.

How does the quality of this intermediate affect final drug formulations?

Impacts the efficacy and safety of Venlafaxine API, ensuring consistency in final dosage forms. Critical for yield optimization and pharmacokinetic properties of the finished drug. Ensures effectiveness and reliability of the Venlafaxine-based antidepressant medications.